ID   HepG2-CAR
DR   Wikidata; Q94103341
RX   Patent=US20190256822;
CC   Population: Caucasian.
CC   Sequence variation: Heterozygous for NRAS p.Gln61Leu (c.182A>T) (ClinVar=VCV000375874) (from parent cell line).
CC   Sequence variation: TERT c.1-124C>T (c.228C>T) (C228T); Note=In promoter (from parent cell line).
CC   Transfected with: HGNC; 7969; NR1I3.
CC   Transfected with: UniProtKB; P13249; S.alboniger pac.
CC   Derived from sampling site: Liver.
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 12-01-21; Version: 5
RX   Patent=US20190256822;
RA   van der Mark V.A.;
RT   "Hepatic cell line resistant to dimethyl sulfoxide, cell culture and
RT   uses thereof.";
RL   Patent number US20190256822, 22-Aug-2019.